Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The company’s shares closed last Friday at p1,466. ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares opened today at ...

The first designs have been released of the housing-led redevelopment of GlaxoSmithKline’s former west London ... Steel from the existing building will be reused to build an extension on the top. The ...

LACMA will give tours of the raw, empty building for donors and members in June, the museum said Tuesday. Musical performances by Kamasi Washington will take place inside the new building June 26 ...

NEW YORK, March 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK). Shareholders who purchased shares of GSK during the class period ...

The U.S. Food and Drug Administration approved British drugmaker GSK's (GSK.L), opens new tab combination vaccine to protect against meningococcal infection for use in people aged 10 through 25 ...

GSK Stock Performance GSK opened at $40.08 on Friday. The firm has a market cap of $83.07 billion, a P/E ratio of 25.21, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58. GSK plc has a ...

With the approval, GSK adds a key new option to its market-leading meningitis vaccine portfolio. In a phase 3 study, GSK's vaccine—given in two doses six months apart—showed immunological ...

Additionally, GSK’s new 5-in-1 meningitis vaccine, Penmenvy, received approval from the US FDA, offering protection against five common serogroups of Neisseria meningitidis for individuals aged ...

To reach that payout under the remuneration committee's proposed new policy, GSK's share price would need to increase by 50%, according to the annual report. It said Walmsley's current pay was ...

GlaxoSmithKline share price jumped more than 17% on Tuesday and extended its surge for the third consecutive session. GlaxoSmithKline shares spiked as much as 17.69% to ₹2,744.95 apiece on the ...